Trials / Completed
CompletedNCT04310709
Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma
Phase II Study of Regorafenib-nivolumab Combination Therapy for Chemotherapy-naïve Patients With Unresectable or Metastatic Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Regorafenib and nivolumab are proven effective agents for the management of unresectable hepatocellular carcinoma patients. As preclinical studies have suggested potential synergism between antiangiogenic agents and immune checkpoint inhibitors, regorafenib and nivolumab may have synergism in terms of efficacy. Herein, this study investigates the combination of regorafenib and nivolumab as first-line therapy in patients with unresectable hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib/Nivolumab | Combination of regorafenib and nivolumab |
Timeline
- Start date
- 2020-06-16
- Primary completion
- 2022-05-30
- Completion
- 2022-11-30
- First posted
- 2020-03-17
- Last updated
- 2022-12-06
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04310709. Inclusion in this directory is not an endorsement.